Evidence map›Paper›PMID 37630974›Full record

ArticlePharmaceuticals (Basel, Switzerland)2023

Characterization of Anticancer Effects of the Analogs of DJ4, a Novel Selective Inhibitor of ROCK and MRCK Kinases.

Vijay Pralhad Kale, Jeremy A Hengst, Arati K Sharma, Upendarrao Golla, Sinisa Dovat, Shantu G Amin, Jong K Yun, Dhimant H Desai

Open access · goldAbstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Vijay Pralhad KaleDepartment of Pharmacology Penn State College of Medicine, Hershey, PA 17033, USA.ORCID 0000-0002-7010-2630
Jeremy A HengstDepartment of Pharmacology Penn State College of Medicine, Hershey, PA 17033, USA.
Arati K SharmaDepartment of Pharmacology Penn State College of Medicine, Hershey, PA 17033, USA.
Upendarrao GollaDepartment of Medicine, Penn State College of Medicine, Hershey, PA 17033, USA.ORCID 0000-0003-0519-7087
Sinisa DovatDepartment of Pediatrics, Penn State College of Medicine, Hershey, PA 17033, USA.
Shantu G AminDepartment of Pharmacology Penn State College of Medicine, Hershey, PA 17033, USA.
Jong K YunDepartment of Pharmacology Penn State College of Medicine, Hershey, PA 17033, USA.ORCID 0000-0001-9476-7795
Dhimant H DesaiDepartment of Pharmacology Penn State College of Medicine, Hershey, PA 17033, USA.ORCID 0000-0001-9367-8600
Penn State Milton S. Hershey Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Rho associated coiled-coil containing protein kinase (ROCK1 and ROCK2) and myotonic dystrophy-related Cdc-42 binding kinases (MRCKα and MRCKβ) are critical regulators of cell proliferation and cell plasticity, a process intimately involved in cancer cell migration and invasion. Previously, we reported the discovery of a novel small molecule (DJ4) selective multi-kinase inhibitor of ROCK1/2 and MRCKα/β. Herein, we further characterized the anti-proliferative and apoptotic effects of DJ4 in non-small cell lung cancer and triple-negative breast cancer cells. To further optimize the ROCK/MRCK inhibitory potency of DJ4, we generated a library of 27 analogs. Among the various structural modifications, we identified four additional active analogs with enhanced ROCK/MRCK inhibitory potency. The anti-proliferative and cell cycle inhibitory effects of the active analogs were examined in non-small cell lung cancer, breast cancer, and melanoma cell lines. The anti-proliferative effectiveness of DJ4 and the active analogs was further demonstrated against a wide array of cancer cell types using the NCI-60 human cancer cell line panel. Lastly, these new analogs were tested for anti-migratory effects in highly invasive MDA-MB-231 breast cancer cells. Together, our results demonstrate that selective inhibitors of ROCK1/2 (DJE4, DJ-Allyl) inhibited cell proliferation and induced cell cycle arrest at G2/M but were less effective in cell death induction compared with dual ROCK1/2 and MRCKα/β (DJ4 and DJ110).

Indexed as

cancerinvasionmetastasisMRCKmulti-kinase inhibitorROCK

Identifiers

PMID37630974
PMCPMC10458458
OpenAlexW4385368421

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.